Home>
News

News

2023

11/08/2023: Asahi Kasei Pharma and SBI Biotech announce start of Phase 1 study to evaluate AK1910 as a potential treatment for autoimmune diseases(PDF/33KB)

2021

07/07/2021: SBI Biotech’s Licensed product, an Anti-ILT7 antibody (HZN-7734) has achieved a Developmental Milestone in a Phase 2 Clinical Trial(PDF/24KB)

2018

07/17/2018: Announcement of new director.[Written in Japanese]

2017

08/28/2017: Our headquarter office is moved to Izumi Garden Tower 15F.

2016

10/21/2016: SBI Biotech’s Licensed product, an Anti-ILT7 antibody (MEDI7734) has achieved a Developmental Milestone in a Phase I Clinical Trial[Written in Japanese]
04/19/2016: SBI Biotech’s Licensed product, an Anti-ILT7 antibody, has IND approval to initiate a Phase Ⅰ Clinical Trial(PDF/39KB)
03/15/2016: SBI Biotech’s Subsidiary Quark Pharmaceuticals Doses First Patients in Two Pivotal Phase III Studies and One Phase II Study of RNAi-Based Therapeutics for Kidney and Eye Indications[Written in Japanese](PDF/154KB)

2015

12/22/2015: Announcement of new director.[Written in Japanese](PDF/119KB)
03/30/2015: Announcement of change of top management.[Written in Japanese](PDF/84KB)

2014

09/16/2014: Announcement of change of top management.[Written in Japanese](PDF/22KB)
06/30/2014: SBI Biotech sells Cdc7/ASK Kinase Inhibitor patent estate to Carna Biosciences, Inc.(Kobe,Japan).[Written in Japanese](PDF/19KB)
03/03/2014: Our headquarter office is moved to Roppongi.
01/04/2014: Announcement of change of top management.[Written in Japanese](PDF/63KB)

2013

12/19/2013

SBI Biotechs Subsidiary Quark Pharmaceuticals and Indias Major Pharmaceutical Company Biocon Enter into a Licensing & Technical Collaboration Agreement was published.(PDF/26KB)

[Related]SBI Holdings, Inc.

[Related]Quark Pharmaceuticals, Inc.

2012

12/27/2012

SBI Biotech Converts Quark Pharmaceuticals, Inc.(California, USA) into a Wholly-owned Subsidiary.(PDF/87KB)

[Related]SBI Holdings, Inc.

[Related]Quark Pharmaceuticals, Inc.

2011

07/19/2011

Kyoto University and Kyoto University Hospital announced to initiate the clinical research by the immuno cell therapy.A clinical trial of immunotherapy using dendritic cells for advanced melanoma

[Related]Kyoto University

[Related]Kyoto University Hospital

06/29/2011

SBI Biotech Initiate Clinical Reseach on Immuno Cell Therapy at Kyoto University was published. (PDF/33KB)

06/24/2011

SBI Biotech exhibits our projects at the 10th INTERNATIONAL BIO FORUM & BIO EXPO JAPAN on June 29 to July 1. Our booth number is 5-84.
Ken-ichi Arai, our president/CEO, attends the Keynote Session "What is Happening in Global pharma world with growing Asia and Synthetic Genome?" as the session chair.

2010

09/14/2010: SBI Biotech exhibits our projects at the Bio Japan 2010 on September 29 to October 1. Our booth number is B604.
06/23/2010: SBI Biotech exhibits our projects at the 9th INTERNATIONAL BIO FORUM & BIO EXPO JAPAN on June 30 to July 2. Ken-ichi Arai, our president/CEO, attends the Keynote Session "Launch an Innovation! The Future of the Biotech Industry and Prospects of Personalized Medicine" as the session chair.

2018

10/14/2008: SBI Biotech Enters Into a Contract with Helixir in Korea to Develop Sarunashi (Hardy Kiwifruits) Extract, PG102 in Japan Exclusively was published.(PDF/47KB)
10/06/2008: SBI Biotech Has Entered Into a License Agreement with Changchun Huapu Biotechnology to Expand Novel Nucleotide Drug Pipeline was published.(PDF/20KB)
10/02/2008: Baylor Research Institute Enters Into a Contract with SBI Biotech to Expand Further Research in DC Technology was published. (PDF/27KB)
09/12/2008: MedImmune Further Expands Autoimmune Disease Research Program Through Collaboration with SBI Biotech was published. (PDF/26KB)